Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06645821 · ClinicalTrials.gov registry record · Early Phase 1
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
A Early Phase 1 study of Hidradenitis Suppurativa (HS), sponsored by Virginia Clinical Research.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06645821: Recruiting Early Phase 1 study of Hidradenitis Suppurativa (HS), sponsored by Virginia Clinical Research.
NCT06645821 is a Early Phase 1 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Virginia Clinical Research. The registered enrollment target is 15 participants, below the 179-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06645821, a Early Phase 1 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Virginia Clinical Research.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are: Does drug EVO101 lower the total number of lesion a participant has from the first visit to the last visit. What medical problems do participants have when applying drug EVO101 Does a participant perceive a change in their hidradenitis suppurativa symptoms based on patient reported outcome questionnaires. Participants will: Apply EVO101 topical cream 0.1% topically Visit the clinic four times unless the first and second appointment have to be done separately then there will be five clinic visits and one phone call over a twelve week period. Keep a dosing diary
Primary Outcome
The change in the total HS lesion count will be assessed at Week 4, Week 8, and Week 12. The percent change from Baseline will be calculated.
Conditions Studied
Interventions
- DRUG EVO101
Study Locations (1)
Virginia
- Virginia Clinical Research, Inc. - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2025-05 |
| Phase | Early Phase 1 |
What NCT06645821 shows while recruiting
NCT06645821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 179-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 1 intervention - of which EVO101 is the first listed.
NCT06645821 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06645821 about?
NCT06645821 is a clinical study titled "Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%". The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are: Does drug EVO101 lower the total number of lesion a participant has from the first visit to the last visit. What medical problems...
What is the current status of trial NCT06645821?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2024-12-03. Estimated completion is 2025-05.
What conditions does trial NCT06645821 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT06645821?
The interventions under investigation include: EVO101 (DRUG).
Who is sponsoring clinical trial NCT06645821?
This trial is sponsored by Virginia Clinical Research, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06645821 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06645821's enrollment target sits among peer trials
15 11th of 12 higher than 2 of 12 other Hidradenitis Suppurativa (HS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa (HS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
RECRUITING · Phase 1
-
Pelashield™ PainGuard™ vs Restrata® in HS Surgery
RECRUITING · NA
-
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI